IMMH-010 / Tianjin Chase Sun Pharma - LARVOL DELTA

Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction. (PubMed, Bioorg Med Chem) - "IMMH-010, as a prodrug of YPD-29B has been approved for clinical phase I by NMPA. We hope these above results could offer a novel perspective for the development of PD-1/PD-L1 small molecule inhibitors."

Journal • Preclinical • Melanoma • Oncology • Solid Tumor • PD-1

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Enrolling by invitation | Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD | N=186 ➔ 96 | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=186 | Enrolling by invitation | Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD | Unknown status ➔ Enrolling by invitation | Phase classification: P1/2 ➔ P1 | N=96 ➔ 186 | Trial completion date: Dec 2021 ➔ Dec 2023 | Trial primary completion date: Sep 2021 ➔ Dec 2023

Enrollment change • Enrollment open • Metastases • Phase classification • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MSI • PD-L1

Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies. (PubMed, Front Pharmacol) - P1/2 | "The results of this study may be useful as a reference for further development of IMMH-010 and PD-L1 inhibitors. Clinical Trial Registration: [https://clinicaltrials.gov/ct2/show/NCT04343859?term=IMMH-010&draw=2&rank=1], identifier [NCT04343859].""

Journal • Preclinical

Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug. (PubMed, Pharmaceutics) - "We also compared the pharmacokinetic profiles of IMMH-010 in rodents and primates. After oral administration of IMMH-010, the general exposure of active metabolite YPD-29B was slightly lower in primates than in rodents, suggesting that data should be extrapolated cautiously from rodents to humans."

Journal • Colon Cancer • Colorectal Cancer • Melanoma • Oncology • Solid Tumor • CES1 • PD-L1

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1/2; N=96; Not yet recruiting; Sponsor: Tianjin Chasesun Pharmaceutical Co., LTD

Clinical • New P1/2 trial